- Voyageur Pharmaceuticals (VM) has received Health Canada approval for its fifth product, MultiXthick barium sulfate suspension
- The product contains 105 per cent w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract
- The company has built a suite of five licensed barium radiographic contrast media products for the CT and fluoroscopy markets
- Voyageur is pursuing FDA device licensing to coincide with its product roll outs
- Voyageur Pharmaceuticals is a drug manufacturing company focused on radiographic contrast media products
- Voyageur Pharmaceuticals (VM) closed the day down 3.33 per cent trading at $0.145 per share
Voyageur Pharmaceuticals (VM) has received Health Canada approval for its fifth product, MultiXthick barium sulphate suspension.
The product contains 105 per cent w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract.
Voyageur has built a full suite of barium radiographic contrast media products for global sales and distribution. It has licensed SmoothX for the CT market and HDX, LDX, MultiXthin and MultiXthick for the fluoroscopy market.
The company is currently optimizing blending formulations and manufacturing procedures to bring its newly-formulated products under GMP and Health Canada guidelines.
Voyageur will be running clinical tests at a Canadian imaging clinic to ensure its products meet and exceed the requirements for computed tomography.
The company is also pursuing FDA device licensing to coincide with its product roll outs.
In addition, Voyageur is working with Dash Consulting to develop new and improved products for the CT, MRI and fluoroscopy markets.
Voyageur Pharmaceuticals is a drug manufacturing company focused on radiographic contrast media products.
Voyageur Pharmaceuticals (VM) closed the day down 3.33 per cent trading at $0.145 per share.
